Study of APG-3288 for Relapsed/Refractory Blood Cancers
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial is testing a new drug called APG-3288 for people with certain relapsed or treatment-resistant blood cancers (like CLL/SLL, DLBCL, MCL, WM, MZL, or FL). You may qualify if you've tried at least 2 prior treatments and are looking for a new option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have one of these blood cancers: CLL/SLL, DLBCL (including Richter Transformation), MCL, WM, MZL, or FL.
- You have already tried at least 2 cancer treatments (including a BTK inhibitor if recommended) and they stopped working or you can't have them.
- Your daily activity level is mostly normal (you can care for yourself and are up and about at least half the day).
- Your organs (like liver, kidneys, bone marrow) are working well enough.
- You are not taking full-dose blood thinners or antiplatelet medications (except low-dose for IV lines).
- You do not have serious uncontrolled heart problems, active infections on treatment, or other active cancers.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies APG-2575 in people with CLL/SLL that has come back or is not responding to prior treatments. It may help shrink disease and improve control when standard options have stopped working.
This trial tests APG-115 alone or with APG-2575 in adults whose T-PLL or NHL has come back or did not respond to treatment. It may help by targeting the cancer cells with a new drug approach when standard therapies have not worked.
This Phase 1/2 study tests APG2575 alone or combined with other treatment in people whose CLL/SLL has come back or did not respond to prior therapy. The goal is to see how well the treatment works and how safe it is.
This trial tests a new drug called APL-4098, given alone or with another medicine, for people with certain blood cancers (AML or MDS) that have come back or not responded to treatment. The goal is to see if it is safe and works well.
This Phase 1 trial tests AC676, a study medicine, for adults with certain B-cell blood cancers that have come back or did not respond to prior treatment. It may help people who have tried standard therapies and need new options.
This trial tests a new drug called CG009301 for people with blood cancers that have come back or haven't responded to standard treatments. The goal is to see if the drug is safe and works against these cancers.
Hear when a new Relapsed/Refractory Hematological Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.